Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-06
2010-06-01
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S267000
Reexamination Certificate
active
07727993
ABSTRACT:
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2Areceptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2Areceptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2Areceptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2Areceptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
REFERENCES:
patent: 5484920 (1996-01-01), Suzuki et al.
patent: 5543415 (1996-08-01), Suzuki et al.
patent: 5587378 (1996-12-01), Suzuki et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 7115614 (2006-10-01), Shimada et al.
patent: 1 016 407 (2000-07-01), None
patent: WO 02/055524 (2002-07-01), None
patent: WO 02/080957 (2002-10-01), None
Konda et al., “Adenosine A2A Antagonist: A Novel Antiparkisonian Agent that Does Not Provoke Dyskinesia in Parkinsonian Monkeys”, Annals of Neurology, vol. 43, No. 4, pp. 507-513 (1998).
Grondin et al., “Antiparkinsonian Effect of a New Selective Adenosine A2A Receptor Antagonist in MPTP-treated Monkeys”, Neuroloy, vol. 52, No. 8, pp. 1673-1677, (1999).
Hashimoto (Pathophysiology of Abnormal Movements in Parkinson's Disease, Nippon Rinsho, Oct. 2000, 58(1): 1994-1999: with Abstract).
Kanda, et al., “Combined Use of the Adenosine A2AAntagonist KW-6002 with L-DOPA or with Selective D1 or D2 . . . ”,Experimental Neurology, vol. 162 (2000), pp. 321-327.
Rashad Net University, Parkinson's Disease: Update, pp. 1-14, www.rashaduniversity.com/mrashad/padiup.html (2005).
Sundstrom, et al., “Chronic neurochemical and behavioral changes in MPTP-lesioned . . . ”, Brain Research, vol. 528 (1990) 181-88.
Fredriksson, et al., “Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice”, J. Neural Transm, vol. 97 (1994) 197-209.
Ossowska, et al., “Blockage of the metabotropic glutamate receptor subtype 5 (mGluR5) products . . . ”, Neuropharmacology, vol. 41 (2001) 413-20.
Ungerstedt, “Postsynaptic Supersensitivity after 6-Hydroxy-dopamine Induced Degeneration . . . ”, Acta Physio. Scand., vol. 367 (1971) 69-93.
Spooren, et al., “Effects of the prototypical mGlu5 receptor antagonist . . . ”, European Journal of Pharmacology, vol. 406 (2000) 403-10.
Cardoso, et al., “Dystonia and Dyskinesia”, Neuropsychiatry of the Basal Ganglia, vol. 20, No. 4 (1997) 821-38.
Diaz-Cabiale, et al, “Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum”, Neurochemistry, vol. 12, No. 9 (2001) 1831-34.
Ferre, et al, “Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease”, Parkinsonism and Related Disorders, vol. 7 (2001) 235-41.
Webster Ross, et al., “Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease”, JAMA, vol. 283, No. 20 (2000) 2674-79.
Popoli, et al., “Effects of SCH 58261, an Adenosine A2A Receptor Antagonist, on Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats: Lack of Tolerance after Chronic Caffeine Intake”, Neuropyschopharmacology, vol. 22, No. 5 (2000) 522-29.
Koga, et al., “Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats”, European Journal of Pharmacology, vol. 408 (2000) 249-55.
Shiozaki, et al, “Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP”, Psychopharmacology, vol. 147 (1999) 90-5.
Kanda, et al., “Adenosine A2A receptors modify motor function in MPTP-treated common marmosets”, Neuropharmacology, vol. 9, No. 12 (1998) 2857-60.
Ferre, et al, “Adenosine-dopamine receptor-receptor interactions as an integrative mechanisms in the basal ganglia”, TINS, vol. 20, No. 10 (1997) 482-87.
Richardson, et al, “Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease”, TiPS, vol. 18 (1997) 338-44.
Fenu, et al., “Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned”, European Journal of Pharmacology, vol. 321 (1997) 143-47.
Pinna, et al., “Blockage of A2A Adenosine Receptors Positively Modulates Turning Behaviour and c-Fos Expression Induced by D1 Agonists in Dopamine-denervated Rats”, European Journal of Neurosciences, vol. 8, No. 6 (1996) 1176-81.
Mally, et al., “Potential Role of Adenosine Antagonist Therapy in Pathological Tremor Disorders”, Pharmacol. Ther., vol. 72, No. 3 (1996) 243-50.
Pollack, et al., “Adenosine Antagonists Potentiate D2 Dopamine-Dependent Activation of Fos in the Striatopallidal Pathway”, Neurosciences, vol. 68, No. 3 (1995) 721-28.
Mally, et al., “The effect of theophylline on parkinsonian symptoms”, J. Pharm. Pharmacol., vol. 46, No. 6 (1994) 515-17.
Kanda, et al., “KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity”, European Journal of Pharmacology, vol. 256 (1994) 263-68.
Schiffmann, et al., “Adenosine A2 Receptors Regulate the Gene Expression of Striatopallidal and Striatonigral Neurons”, The Journal of Neurosciences, vol. 13, No. 3 (1993) 1080-87.
Ferre, et al., “Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes”, Proc. Natl. Acad. Sci., vol. 88 (1991) 7238-41.
Popoli, et al., “Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility”, J. Pharm. Pharmacol., vol. 43, No. 4 (1991) 280-81.
Stromberg, et al., “Further Studies on the Behavioural and Biochemical Interaction between Caffein and L-DOPA”, Journal of Neural Transmission, vol. 34, No. 4 (1973) 241-52.
Grondin, et al., “Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys”, Neurology, vol. 52, No. 8 (1999) 1673-77.
Kanda, et al., “Adenosine A2A Antagonist: A Novel Antiparkinsonian Agent that Does Not Provoke Dyskinesia in Parkinsonian Monkeys”, Ann Neurol, vol. 3, No. 4 (1998), 507-13.
Fernandez, The safety and efficacy of istradefylline, an adenosine A2A antagonist, as monotherapy in early Parkinson disease: Results of the KW-6002-US-051 trial, The Movement Disorder Society's 12th International Congress of Parkinson's Disease and Movement Disorders (2008).
Olanow et al., An Algorithm (Decision Tree) for the Management of Parkinson's Disease: Treatment Guidelines, Neurology, vol. 56, Supp. 5 (2001) 1-111.
Eidelberg et al., Parkinson's Disease, Merck Manuals (2007).
Information Sheet, “Motor Fluctuations in Parkinson's”, Parkinson's Disease Society, XP-001091189, (2009).
Parkinson Study Group, “Entacapone Improves Motor Fluctuations in Levodopa-Treated Parkinson's Disease Patients”, Ann. N
Karasawa Akira
Kase Hiroshi
Kuwana Yoshihisa
Mori Akihisa
Ohsawa Yutaka
Fitzpatrick ,Cella, Harper & Scinto
Kyowa Hakko Kirin Co., Ltd.
Weddington Kevin
LandOfFree
Administering adenosine A 2A receptor antagonist to reduce... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administering adenosine A 2A receptor antagonist to reduce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administering adenosine A 2A receptor antagonist to reduce... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4243205